WESPAC Advisors LLC Makes New $2.93 Million Investment in Merck & Co., Inc. $MRK

WESPAC Advisors LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 27,798 shares of the company’s stock, valued at approximately $2,926,000. Merck & Co., Inc. makes up about 1.6% of WESPAC Advisors LLC’s investment portfolio, making the stock its 12th largest position.

Other institutional investors and hedge funds have also made changes to their positions in the company. DLD Asset Management LP boosted its holdings in Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after buying an additional 11,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Merck & Co., Inc. by 35.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company’s stock valued at $1,540,145,000 after buying an additional 5,094,088 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Merck & Co., Inc. by 192.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 5,496,664 shares of the company’s stock valued at $461,335,000 after acquiring an additional 3,618,532 shares during the period. Amundi lifted its position in shares of Merck & Co., Inc. by 26.4% during the 2nd quarter. Amundi now owns 16,532,657 shares of the company’s stock valued at $1,363,480,000 after acquiring an additional 3,454,941 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of Merck & Co., Inc. by 16.6% during the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after acquiring an additional 2,821,766 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced a US$6.7B acquisition of Terns Pharmaceuticals to add TERN-701 (an investigational oral CML therapy) to its oncology/hematology pipeline—a clear move to build revenue and R&D options ahead of Keytruda’s planned 2028 exclusivity loss. Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition
• Positive Sentiment: RBC reiterated an Outperform and kept a $142 price target after Merck’s Terns call, signaling sell‑side support for the strategy despite questions about the transaction premium. RBC Reiterates Merck (MRK) Outperform
• Positive Sentiment: Agilent won FDA approval for the PD‑L1 22C3 companion diagnostic in esophageal/GEJ carcinoma, which can help identify patients for Keytruda treatment—supportive for near‑term uptake in that indication. Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
• Positive Sentiment: High-profile bullish commentary (e.g., Jim Cramer) and option/trade ideas targeting MRK indicate elevated investor interest and constructive conviction in Merck as a defensive large‑cap pharma. Jim Cramer on Merck & Co.
• Neutral Sentiment: Analyst model tweaks are minor: Erste marginally raised FY2026 EPS estimates (from $5.12 to $5.13), reflecting limited near‑term changes to consensus earnings expectations. MarketBeat analyst update
• Neutral Sentiment: Coverage pieces note Merck has outperformed recently (stock up ~50% over six months); some articles offer tactical trade ideas (options/covered calls) that reflect market momentum rather than fundamental shifts. Merck Stock Soars 50% in 6 Months
• Negative Sentiment: Keytruda’s planned 2028 loss of exclusivity remains the central long‑term risk—analysts and articles stress patent cliff exposure and some weak vaccine sales, which temper valuation upside. Zacks: Merck Stock Soars 50% in 6 Months
• Negative Sentiment: The proposed Terns transaction may face rival interest and is the subject of a shareholder‑lawyer investigation (Kahn Swick & Foti), introducing deal execution, regulatory and legal risk that could delay or change terms. MSN: Merck’s Terns acquisition may face rival interest BusinessWire: KSF Investigation

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $119.77 on Monday. The business’s fifty day moving average price is $116.65 and its two-hundred day moving average price is $102.06. The stock has a market cap of $296.13 billion, a PE ratio of 16.45, a price-to-earnings-growth ratio of 2.31 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same period in the previous year, the firm posted $1.72 earnings per share. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.8%. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Cantor Fitzgerald raised their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. The Goldman Sachs Group boosted their target price on Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Barclays began coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 price target for the company. Finally, Scotiabank boosted their price objective on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research report on Thursday, December 4th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $127.13.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president directly owned 68,916 shares in the company, valued at $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the transaction, the chief financial officer directly owned 90,192 shares in the company, valued at $10,787,865.12. The trade was a 31.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 in the last ninety days. Company insiders own 0.09% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.